Biomerica launches gastrointestinal disease test:
This article was originally published in Clinica
Executive Summary
Biomerica has added to its line of gastrointestinal disease tests with the launch of Pepgen, an ELISA-based test for pepsinogen-I in plasma. Pepsinogen-I is a precursor of the proteolytic enzyme pepsin. Its concentration in plasma is elevated in patients with peptic ulcers, but depressed in patients with gastric cancer. The new test, which can be used in small laboratories with minimal equipment or automated on a laboratory analyser, can thus be used to distinguish between the two conditions. It is available through Biomerica's distributor network in over 40 countries.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.